FBRX Stock On Track For Biggest Single-Day Gains In 20 Months – What’s Behind The Super Rally?
Forte Biosciences announced results from its early-stage study for its investigational drug to treat an autoimmune skin condition.
Read the full articleYou might also wanna read
Forte Biosciences' FB102 shows efficacy in vitiligo Phase 1b study
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
Autoimmune Disease Therapies Market Booms as AbbVie's Skyrizi Poised to Become Second-Best Selling Drug
In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion
forbes.com·1d agoBioLineRx, Hemispherian announces new preclinical data on GLIX1, PARP inhibitor
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
Comments
Sign in to join the conversation.
No comments yet. Be the first.